Hypertensive left ventricular hypertrophy regression: Does it matter?

Current Hypertension Reviews

Volumn 4, Issue 4, 2008, Pages 275-288

  Nadour, Wadih ^a   Biederman, Robert W W ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BRADYKININ B2 RECEPTOR; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOSARTAN; RAMIPRIL; TELMISARTAN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DOWN REGULATION; DRUG CHOICE; DRUG EFFICACY; ELECTRON BEAM TOMOGRAPHY; GENE EXPRESSION; GENE FUNCTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE PRESSURE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; M MODE ECHOCARDIOGRAPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; RENIN RELEASE; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 69049087688     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340208786241309     Document Type: Review

References (123)

1. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 2005; 7(5): 775-82.
2. Abergel E, Tase M, Bohlender J, Menard J, Chatellier G. Which definition for echocardiographic left ventricular hypertrophy? Am J Cardiol 1995; 75: 498-502.
3. Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222-1230.
4. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham heart study. Am J Cardiol 1987; 59: 956-960.
5. Savage DD, Levy D, Dannenberg AL, Garrison RJ, Castelli WP. Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study). Am J Cardiol 1990; 65: 371-376.
6. Daniels SR, Kimball TR, Morrison JA, Khoury P, Witt S, Meyer RA. Effect of lean body mass, fat mass, blood pressure, and sexual maturation on left ventricular mass in children and adolescents: statistical, biological, and clinical significance. Circ 1995; 92: 3249-3254.
7. Himeno E, Nishino K, Nakashima Y, Kuroiwa A, Ikeda M. Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. Am Heart J 1996; 131: 313-319.
8. De Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and Adults: Assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20:1251-60.
9. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham heart study. J Am Coll Cardiol 1995; 25: 879-884.
10. Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive subjects with normal left ventricle mass. J Am Coll Cardiol 1995; 25: 871-878.
11. Homcy CJ. Signaling hypertrophy: how many switches, how many wires? Circ 1998; 97: 1890-1892.
12. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 216-261.
13. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-423.
14. Schunkert H, Sadoshima J, Corneliuus T, et al. Angiotensin II-induced growth responses in isolated adult rat hearts: evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 1995; 76: 489-497.
15. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 258: H610-H618.
16. Mazzolai L, Nussberger J, Aubert JF, et al. Blood pressure-independent cardiac hypertrophy induced by locally activated rennin-angiotensin system. Hypertension 1998; 31: 1324-1330.
17. Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 2006; 21: 20-23.
18. Harrap SB, Dominiczak AF, Frazer R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricle size in healthy young adults. Circ 1996; 93: 1148-1154.
19. Danser AH, Van Kats JP, Admiraal PJ, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24: 37-48.
20. Weinberg EO, Lee MA, Weigner M, et al. Angiotension AT1 receptor inhibition: Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circ 1997; 95: 1592-1600.
21. Harada K, Komuro I, Shiojima E, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circ 1998; 97: 1952-1959.
22. Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circ 1991; 84: 1457-1468.
23. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-228.
24. Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, Lorell BH. Pressure overload induces a severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 1999; 84: 729-734.
25. Zhang W, Kowal RC, Rusnak F, Sikkink RA, Olson EN, Victor RG. Failure of calcineurin inhibitors to prevent pressure - overload left ventricular hypertrophy in rats. Circ Res 1999; 84: 722-728.
26. Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphsim of the angiotensin-converting enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330: 1634-1638.
27. Brull D, Dhamrait S, Myerson S, et al. Bradykinin B2BKR receptor polymorphism and left ventricular growth response. Lancet 2001; 358: 1155-1159.
28. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 1997; 100: 2189-2195.
29. Drazner MH, Dries Dl, Peshock RM, et al. Left ventricular hypertrophy in more prevalent in blacks than whites in the general population: the Dallas Heart Study. Hypertension 2005; 46: 124-129.
30. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994; 26: 279-292.
31. Weber KT, Brilla CG. Pathologic hypertrophy and cardiac interstitium. fibrosis and angiotensin-renin-aldosterone system. Circ 1991; 83: 1849-1865.
32. Schaper J, Speiser B. The extracellular matrix in the failing human heart. Cellular and molecular alterations in the failing human heart. Darmstadt: Steinkopff verlag 1992: 303-313.
33. Villari B, Campbell SE, Hess OM, et al. Influence of the collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 1993; 22: 1477-1484.
34. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases. Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circ 2006: 113; 2089-2096.
35. Villari B, Hess OM, Kaufmann P, Grimm J, Krogmann O, Krayenbuhl HP. Effect of aortic valve stenosis (pressure overload) and regurgitation (volume overload) on left ventricular systolic and diastolic function. Am J Cardiol 1992; 69: 927-934.
36. Hess OM, Villari B, Krayenbuehl HP. Diastolic dysfunction in aortic stenosis. Circ 1993; 87: 73-76.
37. Villari B, Vassalli G, Monrad ES, Chiariello M, Turina M, Hess OM. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circ 1995; 2353-2358.
38. Biederman RWW, Magovern JA, Grant SB, et al. LV reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; Is it durable? A cardiovascular MRI study sponsored by the American Heart Association. Circ In Submission 2008.
39. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circ 1987; 75: 565-567.
40. Devereux RB. Is the electrocardiogram still useful for detection of left ventricular hypertrophy? Circ 1990; 81: 1144-1146.
41. Murphy ML, Thenabadu PN, deSoyza N, Meade J, Doherty JE, Baker BJ. Sensitivity of electrocardiographic criteria for left ventricular hypertrophy according to type of cardiac disease. Am J Cardiol 1985; 55: 545-549.
42. Fragola PV, Colivicchi F, Fabrizi E, Borzi M, Cannata D. Assessment of left ventricular hypertrophy in patients with essential hypertension. A rational basis for the electrocardiogram. Am J Hypertens 1993; 6: 164-169.
43. Sundstrom S, Lind L, Arnlov J, Zethelius B, Adren B, Lithell HO. Echocardiographic and electrocardiographic diagnosis of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circ 2001; 103: 2346-2351.
44. Okin PM, Devereux RB, Nieminen MS, et al. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 2004; 44: 48-54.
45. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricle mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.
46. Casale PN, Devereux RB, Kligfield P, et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol 1985; 6: 572-580
47. Crow RS, Prineas RJ, Rautaharju P, Hannan P, Liebson PR. Relation between electrocardiography and echocardiography for left ventricular mass in mild systemic hypertension. Am J Cardiol 1995; 75: 1233-1238.
48. Korner PI, Jennings GL. Assessment of prevalence of left ventricular hypertrophy in hypertension. J Hypertens 1998; 16: 715-723.
49. Missouris CG, Forbat SM, Singer DR, Markandu ND, Underwood R, Macgregor GA. Echocardiography overestimates left ventricular mass: a comparative study with magnetic resonance imaging in patients with hypertension. J Hypertens1996; 14: 1005-1010
50. Stewart GA, Foster J, Cowan M, et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999; 56: 2248-2253
51. Myerson SG, Montgomery HE, World MJ, Pennell DJ. Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension 2002; 40: 673-678.
52. Nosir Y, Lequin M, Kasprzak J, et al. Measurements and day-to-day variabilities of left ventricular volumes and ejection fraction by three-dimensional echocardiography and comparison with magnetic resonance imaging. Am J Cardiol 1998; 82: 209-214.
53. Altmann K, Shen Z, Boxt L, et al. Comparison of three-dimensional echocardiographic assessment of volume, mass and function in children with functionally single left ventricles with two-dimensional echocardiography and magnetic resonance imaging. Am J Cardiol 1997; 80: 1060-1066.
54. Gopal A, Keller A, Shen Z, et al. Three-dimensional echocardiography: in vitro and in vivo validation of left ventricular mass and comparison with conventional echocardiographic methods. J Am Coll Cardiol 1994; 24: 504-513.
55. Feiring A, Rumberger J, Reiter S, et al. Determination of left ventricular mass in dogs with rapid-acquisition cardiac computed tomographic scanning. Circ 1985; 72: 1355-1364.
56. Mousseaux E, Beygui F, Fornes P, et al. Determination of left ventricular mass with electron beam computed tomography in deformed, hypertrophic human hearts. Eur Heart J 1994; 15: 832-841
57. Schmermund A, Rensing B, Sheedy P, Rumberger J. Reproducibility of right and left ventricular volume measurements by electron-beam CT in patients with congestive heart failure. Int J Card Imaging 1998; 14: 210-209.
58. Katz J, Milliken MC, Stray-Gundersen J, et al. Estimation of human myocardial mass with MR imaging. Radiology 1988; 169: 495- 498.
59. Florentine MS, Grosskreutz CL, Chang W, et al. Measurement of left ventricular mass in vivo using gated nuclear magnetic resonance imaging. J Am Coll Cardiol 1986; 8: 107-112.
60. McDonald K, Parrish T, Wennberg P, et al. Rapid, accurate and simultaneous noninvasive assessment of right and left ventricular mass with nuclear magnetic resonance imaging using the snapshot gradient method. J Am Coll Cardiol 1992; 19: 1601-1607.
61. Germain P, Roul G, Kastler B, Mossard JM, Bareiss P, Sacrez A. Inter-study variability in left ventricular mass measurement. Comparison between M-mode echocardiography and MRI. Eur Heart J 1992; 13: 1011-1019.
62. Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 1995; 8: 221-228.
63. Bellenger NG, Davies LC, Francis JM, Coats ACS, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000; 2: 271-278.
64. Grothues F, Smith GS, Bellenger NG, Collins P, Klein H, Pennell DJ. Comparison of inter-study reproducibility of cardiovascular magnetic resonance and 2D echocardiography in normals, patients with congestive heart failure and in patients with left ventricular hypertrophy. Am J Cardiol 2002; 90: 29-34.
65. Yamaoka O, Yabe T, Okada M, et al. Evaluation of left ventricular mass: Comparison of ultrafast computed tomography, magnetic resonance imaging and contrast left ventriculography. Am Heart J 1993; 126: 1372-1379.
66. Gottdiener J, Livengood S, Meyer P, Chase G. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J Am Coll Cardiol 1995; 25: 424-430.
67. Gosse P, Roudaut R, Dallocchio M. Is echocardiography an adequate method to evaluate left ventricular hypertrophy regression? Eur Heart J 1990; 11: 107-112.
68. Collins H, Kronenberg M, Bryd B. Reproducibility of left ventricular mass measurements by two-dimensional and M-mode echocardiography. J Am Coll Cardiol 1989; 14: 672-676.
69. Devereux RB, Alonso D, Lutas E, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450-458.
70. Palmieri V, Dahlof B, DeQuattro V, et al. Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study. J Am Coll Cardiol 1999: 34: 1625-1632.
71. Gopal A, Schnellbaecher M, Shen Z, et al. Serial assessment of left ventricular mass regression by 3D echocardiography requires three-fold fewer subjects compared to conventional 1D and 2D echocardiography. J Am Coll Cardiol 1996; 81: 150-161.
72. Kuhl H, Bucker A, Franke A, et al. Transesophageal 3-dimensional echocardiography: In vivo determination of left ventricular mass in comparison with magnetic resonance imaging. J Am Soc Echocardiogr 2000; 13: 205-215.
73. Gaudio C, Tanzilli G, Ferri F, et al. Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. J Cardiovasc Pharmacol 1998; 32: 760-768.
74. Johnson D, Foster R, Barilla F, et al. Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction <40% after acute myocardial infarction. J Am Coll Cardiol 1997; 29: 49-54.
75. Myerson SG, Montgomery H, Whittingham M, et al. Left ventricular hypertrophy with exercise and the angiotensin converting enzyme gene I/D polymorphism: a randomized controlled trial with losartan. Circ 2001; 103: 226-230.
76. Francis JM, Pennell DJ. The treatment of claustrophobia during cardiovascular magnetic resonance: use and effectiveness of mild sedation. J Cardiovasc Magn Reson 2000; 2: 139-141.
77. Colan SD. Mechanics of left ventricular systolic and diastolic function in physiologic hypertrophy of the athlete's heart. Cardiol Clin 1997; 15: 355-372.
78. Pluim BM, Lamb HJ, Kayser HW, et al. Functional and metabolic evaluation of the athlete's heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. Circ 1998; 97: 666-672.
79. Dell'Italia JL, Suzanne Oparil S. Cardiac renin angiotensin system in hypertrophy and progression to heart failure. J Heart Failure Rev 1995; 1: 63-72.
80. Verdecchia P, Carini G, Circo A, Dovellini E. Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J Am Coll Cardiol 2001; 38: 1829-1835.
81. Drazner MH, Rame JE, Marino EK, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the cardiovascular health study. J Am Coll Cardiol 2004; 43: 2207-2215.
82. Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circ 2001; 104: 2039-2044.
83. Selvetella G, Notte A, Maffei A, et al. Left ventricular hypertrophy is associated with asymptomatic cerebral damage in hypertensive patients. Stroke 2003; 34: 1766-1770.
84. Levy D, Garrison R, Savage D, Kannel W, Castelli W. Prognostic implications of echocariographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
85. Ghali J, Liao Y, Simmons B, Castaner A, Cao G, Cooper R. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117: 831-836.
86. Kaplinsky E. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther 1994; 8: 549-556.
87. Roman M, Pickering T, Schwartz J, Pini R, Devereux R. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol 1995; 25: 83-90.
88. Kannel W, Cobb J. Left ventricular hypertrophy and mortality: results from the Framingham Study. Cardiology 1992; 81: 291-298.
89. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32: 1454-1459.
90. Gardin JM, McCelland R, Kitzman D, et al. M-mode echocardiographic predictors of six-to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (The Cardiovascular Health Study). Am J Cardiol 2001; 87: 1051-1057.
91. Beache GM, Herzka DA, Boxerman JL, et al. Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. Circ 2001; 104: 1214-1217.
92. Carluccio E, Tommasi S, Bentivoglio M, et al. Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarction. Int J Cardiol 2000; 74: 177-183.
93. Burke PA, Farb A, Liang YH, Smialek J, Virmani R. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circ1996; 94: 3138-3145.
94. Calhoun DA, Oparil S. Treatment of hypertensive crisis. NEJM 1990; 323: 1177-1183
95. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2001; 37: 1042-1048.
96. Norton GR, Woodiwiss AJ, Gaasch WH, et al. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 2002; 39: 664-671.
97. Volders PGA, Sipido KR, Vos MA, Kulcsar A, Verduyn SC, Wellens HJJ. Cellular basis of biventricular hypertropohy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circ 1998; 98: 1136-1147.
98. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program II: mortality by race, sex, and age. JAMA 1979; 24: 2572-2577.
99. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104.
100. Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment of hypertension. Hypertension 1989; 13: 136-144.
101. Collins R, Peto R, MacMahon SW, et al. Blood pressure, stroke, and coronary heart disease, Part 2: Short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
102. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrographic features and their serial changes in subjects with left ventricular hypertrophy. Circ 1994; 90: 1786-1793.
103. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circ 2001; 104: 1615-1621.
104. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-rosei E. Aassociation of change in left ventricular mass with prognosis during long term antihypertensive treatment. J Hypertens 1995; 13: 1091-1095.
105. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circ 1998; 97: 48-54.
106. Hypertension Detection and Follow up-Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension 1985; 7: 105-112.
107. MacMahon S, Collins G, Rautaharju P, et al. Electrocardiographic left ventricular hypertrophy and the effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1989; 63: 202-210.
108. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343-2349.
109. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass during treatment of hypertension. JAMA 2004; 292: 2350-2356.
110. Gonzalez-Fernandez RA, Rivera M, Rondriguez PJ, et al. Prevalence of ectopic ventricular activity after left ventricular mass regression. Am J Hypertens 1993; 6: 308-313.
111. Rials SJ, WU Y, XU X, Filart RA, Marinchak RA, Kowey PR. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness and vulnerability to inducible ventricular fibrillation. Circ 1997; 96: 1330-1336.
112. hospitalization for heart failure in hypertensive patients. Ann Intern Med 2007; 147: 311-319.
113. Mayet J, Ariff B, Wasan B, et al. Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy. Hypertension 2000; 36: 755-759.
114. Schussheim AE, Devereux RB, de Simone G, Borer JS, Herrold EM, Laragh JH. Usefulness of subnormal midwall fractional shortening in predicting left ventricular exercise dysfunction in asymptomatic patients with systemic hypertension. Am J Cardiol 1997; 79: 1070-1074.
115. de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics: an independent predictor of cardiovascular risk in arterial hypertension. Circ 1996; 93: 259-265.
116. Klingbeil AU, Schneider M, Martus P, Messerli FH. A meta analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-46.
117. McMahon LP, Roger SD, Levin A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004; 15: 1640-1647.
118. Okin PM, Devereux RB, Gerdts E, et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy. The Losartan Intervention For Endpoint Reduction in hypertension study. Circ 2006; 113: 1588-1596.
119. Pitt B, Reichek N, Willenbrock R, et al. Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in patients with Essential Hypertension and Left Ventricular Hypertrophy. The 4E- Left Ventricular Hypertrophy Study. Circ 2003; 108: 1831-1838.
120. Galzerano D, Tammaro P, del Viscovo L, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass. Am J Hypertens 2005; 18: 1563-1569.
121. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995; 26: 195-202.
122. Biederman RWW, Doyle M, Young AA, et al. A LIFE magnetic resonance imaging and echocardiography. Hypertension 2008; 52(2): 279-286.
123. Ciulla MM, Paliotti R, Esposito A, et al. Different effects of hypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis. Circ 2004; 110: 552-557.